Algernon Health Stock Price, News & Analysis

Algernon Health (OTCQB: AGNPF) completed its name change from Algernon Pharmaceuticals and will begin trading under the new name on the CSE at market open on October 20, 2025 while retaining the same ticker symbol. The common shares received a new CUSIP 01559C106 and ISIN CA01559C1068; no shareholder action is required.

The company said it will focus on the Alzheimer’s disease diagnostic market by establishing neuroimaging clinics using U.S. FDA-cleared brain-specific PET scanners. Algernon signed a definitive equipment order and financing agreement with Catalyst MedTech for four CareMiBrain PET systems, a non-dilutive deal valued at > CDN $4 million, plus terms to acquire six additional systems on an adjusted-cost basis.

Catalyst MedTech launched the Connect program on October 7, 2025 to expand access to advanced diagnostic imaging by combining its Equipment Solutions and Clinical Solutions businesses.

As part of the launch Catalyst announced a first Connect partnership with Algernon Pharmaceuticals (OTCQB: AGNPF) to advance Optimized Brain PET imaging in the U.S. and establish a dedicated network of neuroimaging clinics for earlier detection of Alzheimer’s. Catalyst will supply a tailored mix of equipment, service, and support, featuring the CareMiBrain system plus the NeuroQ quantitative workstation.

Algernon Pharmaceuticals (OTCQB: AGNPF) has secured a CAD $4 million non-dilutive financing agreement with Catalyst MedTech to acquire four FDA-cleared Oncovision CareMiBrain™ brain-specific PET scanners. The deal includes financing terms with a 20% deposit and 7% annual interest rate, plus an option to acquire six additional systems for future expansion.

The company plans to establish the first dedicated brain-specific PET neuroimaging clinics in the U.S., focusing on early-stage Alzheimer's detection. Each scan will cost approximately US$5,000 and is covered by private insurance, Medicare, and Medicaid. The CareMiBrain™ system offers advanced features including 25% reduced radiation exposure compared to traditional PET/CT scanners and enhanced patient comfort.

Algernon Pharmaceuticals (OTCQB: AGNPF) announced that shareholders approved the creation of a new preferred share class at its annual and special meeting, with over 93% votes in favor. The Series 1 Preferred Shares will include a 10% annual dividend payable in Common or Preferred Shares and are convertible into 10 Common Shares each.

Following the approval, the Company will issue 450,000 Preferred Shares and Preferred Warrants related to a May 2025 acquisition, and 1,268,334 Preferred Shares and 634,167 Preferred Warrants from a July 2025 private placement. Additionally, all five board nominees were elected with over 95% approval. The company also plans to rebrand as Algernon Health Inc. to reflect its expansion into Alzheimer's Disease diagnostics and neuroimaging clinics across North America.

Algernon Pharmaceuticals (OTCQB: AGNPF) has announced its rebranding to Algernon Health, marking a strategic shift towards the Alzheimer's Disease (AD) diagnostic market. The company plans to establish specialized neuroimaging clinics across North America, featuring FDA-cleared brain-specific PET scanning systems that offer lower radiation exposure compared to standard PET/CT machines.

The company's clinics will provide essential amyloid plaque detection services required for FDA-approved AD treatments like Kisunla and Leqembi. These diagnostic services are covered by Medicare, Medicaid, and private insurance in the U.S. The clinics will also offer PET scans for other neurological conditions, including dementia, epilepsy, neuro-oncology, and movement disorders.

Algernon maintains its subsidiary Algernon NeuroScience, focused on DMT research for stroke and brain injury, and holds a 20% stake in Seyltx, which is developing a chronic cough drug.

Algernon Pharmaceuticals (AGNPF) has completed the acquisition of NoBrainer Imaging Centers (NIC), expanding into the Alzheimer's Disease diagnostic and treatment market. The deal grants Algernon exclusive master franchise rights for AD screening centers across Canada and multiple U.S. markets, including Florida (excluding Miami), Los Angeles, and five other major U.S. cities.

The acquisition terms include issuing 5.5 million common shares and warrants, plus 450,000 preferred shares and warrants. NIC brings CAD$250,000 in working capital and a deposit on a Positrigo NeuroLF brain-specific PET scanner, expected for delivery to the first U.S. clinic in Q4 2025. The preferred shares offer a 10% annual dividend and are convertible to common shares at a 1:10 ratio, subject to shareholder approval.

Algernon Pharmaceuticals (AGNPF) has announced its acquisition of NoBrainer Imaging Centers (NIC), marking its entry into the Alzheimer's Disease (AD) diagnostic and treatment market. The company plans to establish comprehensive AD medical clinics across Canada and the U.S., with the first location set to open in Florida in Q4 2025. The clinics will offer: • Advanced PET scan imaging using Positrigo NeuroLF brain PET system • Cognitive and genetic screening including APOE testing • Blood tests for early AD detection • FDA-approved therapy infusions • Personalized wellness programs The company aims to open 10 corporate-owned sites and 10 franchise locations in 2026. The acquisition involves issuing 4.5M common shares, 9M warrants, and 450,000 preferred shares. The deal includes exclusive rights for multiple U.S. markets and Canada, targeting a US$18 billion PET scan market opportunity serving an estimated 7 million AD patients in the U.S. and 750,000 in Canada.

Algernon Pharmaceuticals (OTCQB: AGNPF) has received a notice of allowance from the European Patent Office for its lead chronic kidney disease drug NP-251 (Repirinast). The patent covers the use of Repirinast, alone or combined with telmisartan, for treating renal fibrosis or kidney disease.

The base claims will be valid through 2038, with potential additional protection through adjustments or extensions. The company has already secured patent allowances in the U.S., Japan, and China, with a pending application in Canada.

Key highlights:

• Repirinast reduced fibrosis by 51% with statistical significance in a mouse model
• Showed additive benefits when combined with telmisartan
• Company granted 50,000 restricted share units and 50,000 stock options to consultants, exercisable at $0.09 for five years

Algernon NeuroScience, a subsidiary of Algernon Pharmaceuticals (OTCQB: AGNPF), has appointed Netcapital Securities for its planned Regulation A offering. The company has filed Form 1-A with the SEC, though the offering hasn't been qualified yet.

The proceeds will fund a Phase 2a DMT study involving 40 stroke patients, scheduled for Q3 2025 in Hungary. The study will be led by Dr. Sándor Nardai at the National Institute of Mental Health, Neurology and Neurosurgery in Budapest.

Additionally, the company granted 1,405,000 restricted share units (RSUs) and 1,000,000 stock options at $0.09, exercisable for five years, to executives and directors. Both RSUs and options vest immediately upon grant.